Loading…
Employees: 738
Size CryoPort (CYRX) is a United States Health Care company (Air Freight/Couriers) with a market value of $967M, the 2268th largest of 3,117 United States companies the cockpit tracks. Shares closed at $19.10 on 6 Nov 2026.
Performance Over six months the shares gained 40.4%, against -9.4% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue fell 8.0% over the last twelve months (peer median +4.9%); the operating margin is -21.2% (peer median -39.4%).
Valuation It trades at 4.5× enterprise value to sales against a peer median of 4.4× (7th most expensive of 14).
Capital Return on invested capital runs 21.0 points below its cost of capital (12.6% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $186M | $176M | $157M | $233M | $237M |
| Revenue growth | — | +12% | -33% | -2% | — |
| Gross profit | $74.9M | $70.4M | $57.1M | $83.0M | $88.8M |
| EBITDA | -$13.9M | -$16.8M | -$35.5M | -$31.2M | -$6.97M |
| Net income | -$32.9M | -$38.7M | -$115M | -$99.6M | -$37.3M |
| Free cash flow | -$20.0M | -$25.0M | -$33.6M | -$39.5M | -$24.0M |
| Capital expenditure | $29.3M | $19.5M | $21.3M | $44.9M | $24.2M |
| Total debt | $232M | $231M | $243M | $416M | $436M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Sector in the same market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CYRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +13.0% | +0.7% | 3rd highest of 20 |
| 6-month return | +40.4% | -9.4% | 3rd highest of 19 |
| Distance from 52-week high | -2.2% | -37.2% | highest of 21 |
| Revenue growth (TTM) | -8.0% | +4.9% | 4th lowest of 15 |
| Operating margin | -21.2% | -39.4% | 8th highest of 15 |
| EV / Sales | 4.5× | 4.4× | 7th most expensive of 14 |
| ROIC minus cost of capital | -21.0 pp | -4.9 pp | 3rd lowest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CryoPort CYRX | United States | $967M | +40% | -8% | -21% | 4.5× | n/a | n/a |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $981M | -32% | n/a | n/a | n/a | n/a | n/a |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | 10.7× | n/a | n/a |
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 2.8× | n/a | n/a |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | 2.1× | n/a | n/a |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | 0.9× | 16.3% | +25.2% |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 4.4× | 51.8% | +41.0% |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a | n/a |
| Oric Pharmaceuticals ORIC | United States | $914M | 0% | n/a | n/a | n/a | n/a | n/a |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | 8.6× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 1.6× | 5.2% | +3.6% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 2.0× | 6.9% | +12.1% |
| Corvus Pharmaceuticals CRVS | United States | $887M | -32% | n/a | n/a | n/a | n/a | n/a |
| Aktis Oncology AKTS | United States | $880M | -15% | +337% | -1,150% | 57.5× | n/a | n/a |
| BellRing Brands BRBR | United States | $1.07B | -11% | +6% | 13% | 0.9× | -17.4% | +18.6% |